Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology
14. November 2017 07:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. (www.neuronascent.com), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today...
Neuronascent Appoints New Board Member
12. April 2017 06:30 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - April 12, 2017) - Neuronascent, Inc., a neuro-pharmaceutical company developing proprietary therapeutics for Alzheimer's disease, Parkinson's disease, and psychiatric...
Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders
24. Januar 2017 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - January 24, 2017) - Neuronascent's U.S. Patent No. 9,539,261, which issued on January 10, 2017, claims methods of stimulating neurogenesis and/or inhibiting neuronal...
Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic
06. April 2015 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Apr 6, 2015) - Neuronascent, a biopharmaceutical company developing non-invasive, neuron regenerative therapeutics aimed at reversing cognitive deficits in...
Neuronascent Announces Expanded Patent Coverage in US and Russia for Its Alzheimer's Disease and Down Syndrome Therapeutics
05. Februar 2015 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Feb 5, 2015) - The US Patent Office issued an allowance to Neuronascent, Inc. expanding patent protection of their new therapeutic candidate, NNI-362, beyond...
Neuronascent Successfully Completes Pre-IND Meeting With FDA for Alzheimer's Disease Therapeutic
22. April 2014 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Apr 22, 2014) - Neuronascent, Inc. (www.neuronascent.com), a company focused on developing its novel therapeutic candidates for new neuron formation in Alzheimer's...
Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate
29. Januar 2014 07:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Jan 29, 2014) - Neuronascent, Inc. announced today the issuance of the United States patent covering a new compound family that includes Neuronascent's lead...
Neuronascent, Inc. Alzheimer's Disease Therapeutic Candidate Selected for Preclinical Safety Testing
19. November 2013 07:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Nov 19, 2013) - Neuronascent, Inc. (www.neuronascent.com) announced today that preclinical development of Neuronascent's (the "Company") innovative Alzheimer's...
Neuronascent, Inc. Announces Issuance of Canadian Patent Covering Its Lead Alzheimer's Disease Candidate
25. Juni 2013 12:39 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - Jun 25, 2013) - Neuronascent, Inc. announced today the issuance of a Canadian patent covering its compound families that include Neuronascent's Alzheimer's...
Neuronascent Issued US Patent for Neurogenesis, Therapeutic Candidates
26. Oktober 2011 12:51 ET
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwire - Oct 26, 2011) - Neuronascent, Inc. (www.neuronascent.com) announced today that the USPTO has allowed claims for its patent, "Methods and Compositions for Stimulating...